Trump's Tariff Tango: Pharmaceutical and Metal Sectors Brace for Impact

President Trump signed an executive order potentially imposing up to 100% tariffs on patented pharmaceuticals from companies without pricing deals with the US. The order, seeking to address national security threats, coincides with updated metal tariffs, reflecting Trump's broader strategy of using tariffs in trade negotiations.

US President Donald Trump has taken a significant step by signing an executive order that could target certain patented drugs with tariffs of up to 100%. Companies without pricing agreements with the administration may feel the heat of this decision.

In a bid to boost domestic manufacturing, those investing in US-based facilities will avoid tariffs. Firms without current deals yet investing will see a 20% tariff, potentially rising to 100% over time. This move aligns with Trump's strategy to renegotiate deals and address what he describes as threats to national security.

A simultaneous announcement on metal tariffs has also generated discussions. Tariff calculations for imported steel, aluminum, and copper products have been revised, spotlighting Trump's ongoing inclination to employ tariffs as economic tools, despite concerns from various industry leaders and potential legal challenges.

(With inputs from agencies.)